Against the backdrop of China’s dual-carbon goals and the upgrading of the biomanufacturing industry, bio-based sugar alcohols, leveraging their renewable and environmentally friendly advantages, have become a key driver for high-value industrial transformation. Bio-based mannitol, a naturally occurring six-carbon sugar alcohol, can be extracted from brown algae and corn starch or synthesized via biocatalytic routes, combining diversified application attributes with high added value. By 2025, China’s mannitol production capacity is expected to reach 235,000 tons, with a capacity utilization rate of 85.5% and bio-based processes accounting for more than 67%, gradually replacing traditional chemical synthesis routes. This transition is enabling high-value conversion across pharmaceuticals, new energy, food, and other sectors, supporting quality and efficiency upgrades in biomanufacturing.
1. Technological breakthroughs are driving green upgrading of production processes.
Bio-based mannitol technologies continue to evolve, with dual-enzyme cascade catalysis and engineered microbial strain modification as core development directions. Domestic research has achieved a molar conversion rate of 81.9% by optimizing Escherichia coli bioconversion conditions, enabling efficient synthesis, while other research teams have further reduced production costs by more than 30% through yeast strain engineering. Compared with traditional hydrogenation processes, bio-based routes reduce carbon emissions by approximately 35%, aligning with green transformation requirements and promoting low-energy, high-efficiency industrial upgrading.
2. Deepened pharmaceutical applications highlight high-value attributes.
Bio-based mannitol is an important precursor for antitumor drugs and immunostimulants, and as an injectable-grade excipient, it can regulate osmotic pressure and is widely used in contrast agents and sustained-release formulations. In 2023, the injectable-grade mannitol market reached RMB 680 million, with a growth rate exceeding 12%. High-purity products have achieved purity levels above 99.5% and comply with pharmacopeial standards. With advantages such as low toxicity and no impact on blood glucose levels, bio-based mannitol is seeing expanding applications in sugar-free pharmaceuticals and oral care medications, supporting the high-value development of the pharmaceutical sector.
3. Cross-sector application expansion is broadening growth boundaries.
Bio-based mannitol is increasingly penetrating new energy and food sectors. In the new energy field, its derivatives can be converted into microbial oils, providing a pathway for third-generation biofuels, with oleic acid accounting for nearly 70%. In the food industry, mannitol serves as a low-calorie sweetener with approximately 62% of the sweetness of sucrose, making it suitable for sugar-free foods and beverages, and its market share in the sweetener segment has risen to 19%. Meanwhile, applications in cosmetic humectants and biodegradable materials are also making steady breakthroughs.
4. Market-driven demand is expanding industry scale. China’s bio-based mannitol
market is growing steadily, with the market size projected to increase from RMB 2.86 billion in 2024 to RMB 4.53 billion by 2030, representing a compound annual growth rate of 7.9%. The food sector accounts for 54% of total demand, while pharmaceutical-grade products deliver gross margins of 42%, driving enterprises to increase R&D investment. Export performance remains strong, with exports expected to account for 31% of total output by 2025, and demand growth in Southeast Asia exceeding 15%, forming a dual-circulation development pattern driven by both domestic and international markets.
5. Policy support is unlocking industry growth potential. The Healthy China 2030.
initiative supports the development of functional sugar alcohols, while the revised National Food Additive Use Standards released in 2024 have relaxed allowable addition limits. Environmental regulations are accelerating the phase-out of traditional processes, with more than 60% of production capacity expected to complete bio-based upgrading by the end of 2025. Industry concentration continues to rise, with leading enterprises accounting for 57% of market share, and through supply chain integration and process optimization, the industry is moving toward standardized and high-quality development.
Conclusion
Driven by technological breakthroughs and diversified application adaptability, bio-based mannitol has become a core carrier for high-value conversion in biomanufacturing. Looking ahead, supported by strain optimization, cross-sector application expansion, and favorable policy frameworks, its strategic value will become increasingly prominent. The industry should continue to focus on process innovation, quality control, and deeper industrial chain collaboration, accelerating product upgrading and providing strong support for the high-quality development of the biomanufacturing sector.
